RxDoctor Payments Data

Leslee Bartell, APRN

Nurse Practitioner · Topeka, KSNPI 1669783684

Payments from drug & device makers

$1,375in general payments, 2019–2025

Across 35 payments — averaging $39.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ascensia Diabetes Care US Inc.$359
  • Novo Nordisk$329
  • Dexcom, Inc.$167
  • Sanofi-aventis U.S. LLC$107
  • GRT US Holding, Inc.$89
  • Mannkind Corporation$73
  • plus $249 from 6 others

What the payments were for

  • Food & beverage$1,375100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,375 in reported general payments places this provider in the 80th percentile of 1,326 nurse practitioner providers in Kansas.

See all nurse practitioner providers in Kansas

Medicare billing

Part B allowed, 2024
$121,697
Medicare patients
526
Services billed
4,070

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide360$517,992
JardianceEmpagliflozin289$263,443
MounjaroTirzepatide171$196,940
Tresiba Flextouch U-200Insulin Degludec56$92,918
Humulin R U-500 KwikpenInsulin Regular, Human89$92,909
FarxigaDapagliflozin Propanediol86$82,865
TrulicityDulaglutide70$76,705
Teriparatide22$57,488
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog73$31,560
RybelsusSemaglutide14$30,112
Tresiba Flextouch U-100Insulin Degludec66$28,431
Lantus SolostarInsulin Glargine,hum.Rec.Anlog134$20,735
Fiasp FlextouchInsulin Aspart (Niacinamide)13$13,946
SynthroidLevothyroxine Sodium166$13,842
Novolog FlexpenInsulin Aspart75$13,797

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$329$548,103374 claims
Boehringer IngelheimJardiance$18$263,443289 claims
AstraZenecaFarxiga$42$82,86586 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,326 nurse practitioner providers in Kansas.

Other nurse practitioner in Topeka

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →